Trial Profile
Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications POEMS syndrome
- Focus Pharmacodynamics
- 27 Jul 2016 Status changed from recruiting to completed.
- 28 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov
- 29 Jul 2014 New source identified and integrated (University Hospital Medical Information Network - Japan)